The document lists several new drugs approved in 2019 including Esketamine nasal spray for treatment resistant depression, Netarsudil + Latanoprost FDC for open angle glaucoma, and Trastuzumab + Hyaluronidase FDC for HER2 positive breast cancer. It also mentions new drugs for conditions such as postpartum depression, cardiomyopathy, plaque psoriasis, spinal muscular atrophy, diffuse large B cell lymphoma, chronic lymphocytic leukemia, hepatocellular carcinoma, Lambert Eaton myasthenic syndrome, dengue, acute GVHD, axial spondylarthritis, osteoporosis, relapsing multiple sclerosis, renal cell carcinoma, and various types of cancer
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
0 ratings0% found this document useful (0 votes)
210 views6 pages
New Drugs 2019: New Drug Mechanism of Action Use
The document lists several new drugs approved in 2019 including Esketamine nasal spray for treatment resistant depression, Netarsudil + Latanoprost FDC for open angle glaucoma, and Trastuzumab + Hyaluronidase FDC for HER2 positive breast cancer. It also mentions new drugs for conditions such as postpartum depression, cardiomyopathy, plaque psoriasis, spinal muscular atrophy, diffuse large B cell lymphoma, chronic lymphocytic leukemia, hepatocellular carcinoma, Lambert Eaton myasthenic syndrome, dengue, acute GVHD, axial spondylarthritis, osteoporosis, relapsing multiple sclerosis, renal cell carcinoma, and various types of cancer
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 6
New Drugs 2019
Dr. Ranjan Kumar Patel
New Drug Mechanism of Action Use Esketamine nasal NMDA antagonist Resistant depression spray Netarsudil + Netarsudil is a rho kinase inhibitor Open angle glaucoma Latanoprost FDC and latanoprost is a prostaglandin ophthalmic F2alpha analog solution Trastuzumab + Hyaluronidase increases Her2 positive breast cancer Hyaluronidase absorption rate of trastuzumab FDC Triclabendazole Benzimidazole which inhibits Liver flukes microtubules Caplacizumab Anti von Willebrand factor Acquired monoclonal antibody which blocks thrombocytopenic purpura adhesion of platelets to blood vessels Parabotulinum Inhibits release of acetylcholine Temporary improvement toxin A in glabellar lines associated with corrugator and/or procerus muscle activity in adults Brexanolone GABA-A receptor modulator Postpartum depression Tafamidis Oral transthyretin stabilizer Cardiomyopathy of wild meglumine type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) Risankizumab Anti IL-23 monoclonal antibody Plaque psoriasis Onasemnogene Adeno-associated virus vector- Spinal muscular atrophy abeparvovec based gene therapy (SMA) in children < 2 years
75 Hours of Online Pharmacology Videos at www.pharmle.com
New Drugs 2019 Dr. Ranjan Kumar Patel Polatuzumab Immunotoxin made up of Used along with vedotin polatuzumab (anti CD 79b MAb) bendamustine and and vedotin (toxin) rituximab for treatment of diffuse large B cell lymphoma Venetoclax and Venetoclax is a BCL-2 inhibitor and Chronic lymphocytic Obinutuzumab Obinutuzumab is an anti CD 20 leukemia and small FDC monoclonal antibody lymphocytic lymphoma Ramucirumab Anti VEGFR monoclonal antibody Hepatocellular carcinoma in patients having alpha feto protein levels > 400 ng/ml, despite being treated with sorafenib Amifampridine Potassium channel blocker Lambert Eaton myasthenic syndrome in patients of 6- 17 years age Dengvaxia Recombinant live tetravalent Prevention of dengue dengue vaccine caused by serotypes 1-4 only in age group 9-16 years with laboratory confirmed previous dengue infection Ruxilotinib JAK 1 and 2 inhibitor Treatment of steroid resistant acute GVHD in age group more than 12 years Certolizumab Anti TNF alpha drug Treatment of active non- radiographic axial spondylarthritis with objective signs of inflammation
75 Hours of Online Pharmacology Videos at www.pharmle.com
New Drugs 2019 Dr. Ranjan Kumar Patel Romosozumab Antisclerostin monoclonal antibody Osteoporosis in postmenopausal females with high risk of fracture Cladribine Purine analog Relapsing form of multiple sclerosis Siponimod Sphingosine 1-phosphate receptor Relapsing form of multiple modulator sclerosis Avelumab plus Avelumab is an anti-programmed Combination therapy has Axitinib death ligand 1 monoclonal been approved for antibody and axitinib is a VEGFR treatment of renal cell tyrosine kinase inhibitor carcinoma Pembrolizumab Pembrolizumab is an anti- Renal cell carcinoma programmed death ligand 1 Advanced endometrial receptor monoclonal antibody carcinoma Squamous cell cancer of esophagus Small and non-small cell lung cancer
Intranasal GABA A receptor agonist Acute repetitive seizures in
midazolam spray age group > 12 years of age Solriamfetol Dopamine and norepinephrine Excessive sleepiness reuptake inhibitor associated with narcolepsy and obstructive sleep apnea Alpelisib Phosphatidyl inositol 3 kinase Treatment of ER+ breast (PI3K) inhibitor cancer in postmenopausal females with PI3KCA mutation in combination with fluvestrant
75 Hours of Online Pharmacology Videos at www.pharmle.com
New Drugs 2019 Dr. Ranjan Kumar Patel Atezolizumab Anti-programmed death cell ligand Used along with paclitaxel 1 monoclonal antibody for treatment of triple negative breast cancer which is unresectable or locally advanced Erdafitinib Fibroblast growth factor receptor Locally advanced or tyrosine kinase inhibitor metastatic urothelial carcinoma Apremilast Phosphodiesterase-4 inhibitor Oral ulcers associated with Bechet’s syndrome Oral semaglutide It is the first oral GLP-1 agonist. It is Type II diabetes mellitus to be taken exactly 30 minutes before the first food of the day. Sodium caprylate is added to semaglutide to increase its intestinal absorption. Tenapanor Sodium/hydrogen exchanger 3 IBS associated with (NHE3) inhibitor. constipation NHE3 is an antiporter that absorbs sodium in the intestine in exchange for proton. Hence its inhibition increases sodium in intestine, that draws water. Relebactam Beta lactamase inhibitor Approved to be used with imipenem + cilastatin for treatment of complicated UTI and intraabdominal infections Fedratinib Oral Janus Associated Kinase 2 Myelofibrosis (JAK2) and FMS-like tyrosine kinase 3 (FLT3) inhibitor
75 Hours of Online Pharmacology Videos at www.pharmle.com
New Drugs 2019 Dr. Ranjan Kumar Patel Selinexor Nuclear export inhibitor Resistant multiple By inhibition of export of tumor myeloma suppressor proteins from nucleus of cancer cells, it induces apoptosis of cancer cells. Nintedanib Multiple tyrosine kinase inhibitor Systemic sclerosis associated interstitial lung disease Pretomanid Mycolic acid synthesis inhibitor Approved for treatment of XDR TB along with bedaquiline and linezolid Lefamulin Protein synthesis inhibitor which Community acquired acts by inhibiting peptidyl pneumonia transferase Upadacitinib Oral JAK inhibitor Methotrexate resistant rheumatoid arthritis Ixekizumab Anti-IL17A monoclonal antibody Active ankylosing spondylitis Pitolisant Histamine-3 (H3) receptor Narcolepsy antagonist/inverse agonist Istradefylline Adenosine A2A receptor antagonist On-off phenomena seen with levodopa Bremelanotide Melanocortin peptide receptors Hypoactive sexual desire agonist disorder in premenopausal females Darolutamide Androgen receptor inhibitor Non-metastatic castration resistant prostate cancer Entrectinib Multiple kinase (RTL, ROS1, ALK) ROS1 positive metastatic inhibitor non-small cell lung cancer
75 Hours of Online Pharmacology Videos at www.pharmle.com
New Drugs 2019 Dr. Ranjan Kumar Patel Pexidartinib Multi-kinase inhibitor Symptomatic tenosynovial giant cell tumor
75 Hours of Online Pharmacology Videos at www.pharmle.com